Business
Covalon Secures National Research Council Funding for Antimicrobial Coating of Orthopaedic Implants
Covalon Secures National Research Council Funding for Antimicrobial Coating of Orthopaedic Implants
About this update from Covalon Technologies Ltd.
[{"type":"text","content":"\n\n\n\n Jun. 29, 2010 (Canada NewsWire Group) -- Covalon Technologies Ltd. (the "Company" or "Covalon") (TSX-V: COV), an advanced medical technology company, is pleased to announce that it has been approved for research funding from the National Research Council of Canada that will assist Covalon in the commercialization of its antimicrobial coatings for orthopaedic implants fabricated from metal. The funding from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) is for approximately $150,000, in addition to both technical and business oriented advisory services.\n"As a global leader of advanced medical coatings, Covalon appreciates the financial support provided by the National Research Council for the commercial development of this unique coating application," stated Dr. Val DiTizio, Covalon's Chief Scientific Officer. "This funding will assist Covalon in addressing the issues of serious infections and device failure that face many medical companies in the large orthopaedic implant market."\nThe market for orthopaedic implants and fixtures is growing rapidly due to a large and aging population, with an estimated three million procedures performed annually in the United States alone. Without an antimicrobial coating for orthopedic hardware, patients undergoing medical device implants are at risk of acquiring serious infections causing device failure with debilitating consequences. Other medical devices coated with antimicrobial technology have demonstrated dramatically improved patient outcomes and lower treatment costs through the reduction of serious infections.\n"The National Research Council funding will allow Covalon to apply our coating technologies on orthopedic implants. The failure of these implants due to infection is catastrophic for many patients, and can be life-threatening," said William Jackson, Covalon's Chief Business Officer. "The ability to decrease these adverse events will revolutionize the orthopedic industry".\n\nAbout Covalon\n\nCovalon Technologies Ltd. is a unique medical technologies company engaged in the research, development, and commercialization of advanced tissue repair applications, infection control, and specialized coatings for medical and consumer products. Together, our technology platforms,...